In a welcome move, Pacira BioSciences saw its Relative Strength Rating rise from 70 to 76 on Friday.
How To Invest In Stocks In Both Bull And Bear Markets
IBD's unique RS Rating tracks market leadership by using a 1 (worst) to 99 (best) score that indicates how a stock's price performance over the trailing 52 weeks matched up against all other stocks.
History reveals that the best stocks tend to have an RS Rating north of 80 in the early stages of their moves. See if Pacira BioSciences can continue to show renewed price strength and hit that benchmark.
Pacira BioSciences is trying to complete a consolidation with a 27.64 entry. See if it can break out in volume at least 40% above average.
The company posted 0% EPS growth in its most recent report, while sales growth came in at 1%. Look for the next report on or around Aug. 5.
Pacira BioSciences holds the No. 59 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and Inhibrx Biosciences are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
